Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis

<p>Abstract</p> <p>Background</p> <p>Tumour regression observed in many conditional mouse models following oncogene inactivation provides the impetus to develop, and a platform to preclinically evaluate, novel therapeutics to inactivate specific oncogenes. Inactivating...

Full description

Bibliographic Details
Main Authors: Zervou Sevasti, Ifandi Vasiliki, Cheung Linda, Abouna Sylvie, Pelengaris Stella, Khan Michael
Format: Article
Language:English
Published: BMC 2004-12-01
Series:BMC Biology
Online Access:http://www.biomedcentral.com/1741-7007/2/26
_version_ 1818353689707937792
author Zervou Sevasti
Ifandi Vasiliki
Cheung Linda
Abouna Sylvie
Pelengaris Stella
Khan Michael
author_facet Zervou Sevasti
Ifandi Vasiliki
Cheung Linda
Abouna Sylvie
Pelengaris Stella
Khan Michael
author_sort Zervou Sevasti
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Tumour regression observed in many conditional mouse models following oncogene inactivation provides the impetus to develop, and a platform to preclinically evaluate, novel therapeutics to inactivate specific oncogenes. Inactivating single oncogenes, such as c-Myc, can reverse even advanced tumours. Intriguingly, transient c-Myc inactivation proved sufficient for sustained osteosarcoma regression; the resulting osteocyte differentiation potentially explaining loss of c-Myc's oncogenic properties. But would this apply to other tumours?</p> <p>Results</p> <p>We show that brief inactivation of c-Myc does not sustain tumour regression in two distinct tissue types; tumour cells in pancreatic islets and skin epidermis continue to avoid apoptosis after c-Myc reactivation, by virtue of Bcl-x<sub>L </sub>over-expression or a favourable microenvironment, respectively. Moreover, tumours progress despite reacquiring a differentiated phenotype and partial loss of vasculature during c-Myc inactivation. Interestingly, reactivating c-Myc in β-cell tumours appears to result not only in further growth of the tumour, but also re-expansion of the accompanying angiogenesis and more pronounced β-cell invasion (adenocarcinoma).</p> <p>Conclusions</p> <p>Given that transient c-Myc inactivation could under some circumstances produce sustained tumour regression, the possible application of this potentially less toxic strategy in treating other tumours has been suggested. We show that brief inactivation of c-Myc fails to sustain tumour regression in two distinct models of tumourigenesis: pancreatic islets and skin epidermis. These findings challenge the potential for cancer therapies aimed at transient oncogene inactivation, at least under those circumstances where tumour cell differentiation and alteration of epigenetic context fail to reinstate apoptosis. Together, these results suggest that treatment schedules will need to be informed by knowledge of the molecular basis and environmental context of any given cancer.</p>
first_indexed 2024-12-13T19:13:31Z
format Article
id doaj.art-540f2a6e83ba4d4683ec259b8ce04942
institution Directory Open Access Journal
issn 1741-7007
language English
last_indexed 2024-12-13T19:13:31Z
publishDate 2004-12-01
publisher BMC
record_format Article
series BMC Biology
spelling doaj.art-540f2a6e83ba4d4683ec259b8ce049422022-12-21T23:34:21ZengBMCBMC Biology1741-70072004-12-01212610.1186/1741-7007-2-26Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermisZervou SevastiIfandi VasilikiCheung LindaAbouna SylviePelengaris StellaKhan Michael<p>Abstract</p> <p>Background</p> <p>Tumour regression observed in many conditional mouse models following oncogene inactivation provides the impetus to develop, and a platform to preclinically evaluate, novel therapeutics to inactivate specific oncogenes. Inactivating single oncogenes, such as c-Myc, can reverse even advanced tumours. Intriguingly, transient c-Myc inactivation proved sufficient for sustained osteosarcoma regression; the resulting osteocyte differentiation potentially explaining loss of c-Myc's oncogenic properties. But would this apply to other tumours?</p> <p>Results</p> <p>We show that brief inactivation of c-Myc does not sustain tumour regression in two distinct tissue types; tumour cells in pancreatic islets and skin epidermis continue to avoid apoptosis after c-Myc reactivation, by virtue of Bcl-x<sub>L </sub>over-expression or a favourable microenvironment, respectively. Moreover, tumours progress despite reacquiring a differentiated phenotype and partial loss of vasculature during c-Myc inactivation. Interestingly, reactivating c-Myc in β-cell tumours appears to result not only in further growth of the tumour, but also re-expansion of the accompanying angiogenesis and more pronounced β-cell invasion (adenocarcinoma).</p> <p>Conclusions</p> <p>Given that transient c-Myc inactivation could under some circumstances produce sustained tumour regression, the possible application of this potentially less toxic strategy in treating other tumours has been suggested. We show that brief inactivation of c-Myc fails to sustain tumour regression in two distinct models of tumourigenesis: pancreatic islets and skin epidermis. These findings challenge the potential for cancer therapies aimed at transient oncogene inactivation, at least under those circumstances where tumour cell differentiation and alteration of epigenetic context fail to reinstate apoptosis. Together, these results suggest that treatment schedules will need to be informed by knowledge of the molecular basis and environmental context of any given cancer.</p>http://www.biomedcentral.com/1741-7007/2/26
spellingShingle Zervou Sevasti
Ifandi Vasiliki
Cheung Linda
Abouna Sylvie
Pelengaris Stella
Khan Michael
Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis
BMC Biology
title Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis
title_full Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis
title_fullStr Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis
title_full_unstemmed Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis
title_short Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis
title_sort brief inactivation of c myc is not sufficient for sustained regression of c myc induced tumours of pancreatic islets and skin epidermis
url http://www.biomedcentral.com/1741-7007/2/26
work_keys_str_mv AT zervousevasti briefinactivationofcmycisnotsufficientforsustainedregressionofcmycinducedtumoursofpancreaticisletsandskinepidermis
AT ifandivasiliki briefinactivationofcmycisnotsufficientforsustainedregressionofcmycinducedtumoursofpancreaticisletsandskinepidermis
AT cheunglinda briefinactivationofcmycisnotsufficientforsustainedregressionofcmycinducedtumoursofpancreaticisletsandskinepidermis
AT abounasylvie briefinactivationofcmycisnotsufficientforsustainedregressionofcmycinducedtumoursofpancreaticisletsandskinepidermis
AT pelengarisstella briefinactivationofcmycisnotsufficientforsustainedregressionofcmycinducedtumoursofpancreaticisletsandskinepidermis
AT khanmichael briefinactivationofcmycisnotsufficientforsustainedregressionofcmycinducedtumoursofpancreaticisletsandskinepidermis